Information on BPC-157 dosages comes primarily from preclinical studies and research protocols
the FDA has stated it lacks sufficient information to know whether the substance would cause harm when administered to humans Evidence snapshot: The evidence base is almost entirely preclinical, decades of animal (largely rat) studies, mostly from one Croatian research group (Sikiric et al., University of Zagreb), with a single small human trial under the brand name "Bepecin" (around 2015) that did not lead to any FDA-approved use
OPM database and PPM web server: resources for positioning of proteins in membranes
Best for: MTHFR mutations (C677T, A1298C) Supporting methylation directly Neurological symptoms (brain fog, neuropathy) Depression and mood disorders Elevated homocysteine Advantages: No conversion required immediately bioavailable Directly supports methylation cycle Crosses blood-brain barrier easily Lowers homocysteine effectively Potential downsides: Can cause overmethylation symptoms in sensitive individuals (anxiety, insomnia, irritability) May need to start with very low doses Not ideal for those with histamine issues or overmethylators Typical dosage: 500-5000mcg daily (start low) 2
Fibrosis modulation helping limit the overgrowth of scar tissue in soft tissues and organs*
